StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Keros Therapeutics's total assets was $287.60M at Jun 30, 2026. For fiscal 2025 it was $338.02M, down 45.1% from the year before. The highest annual figure on record is $615.89M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$338.02M-45.1%
FY2024Dec 31, 2024$615.89M+66.4%
FY2023Dec 31, 2023$370.03M+20.6%
FY2022Dec 31, 2022$306.78M+20.2%
FY2021Dec 31, 2021$255.25M-5.3%
FY2020Dec 31, 2020$269.44M+2359.5%
FY2019Dec 31, 2019$10.96M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$287.60M-62.0%
Q1 FY2026Mar 31, 2026$312.29M-60.2%
Q4 FY2025Dec 31, 2025$338.02M-45.1%
Q3 FY2025Sep 30, 2025$742.78M+28.2%
Q2 FY2025Jun 30, 2025$757.17M+66.4%
Q1 FY2025Mar 31, 2025$784.56M+61.5%
Q4 FY2024Dec 31, 2024$615.89M+66.4%
Q3 FY2024Sep 30, 2024$579.27M+77.6%
Q2 FY2024Jun 30, 2024$455.02M+27.7%
Q1 FY2024Mar 31, 2024$485.82M+26.4%
Q4 FY2023Dec 31, 2023$370.03M+20.6%
Q3 FY2023Sep 30, 2023$326.25M+29.2%
Q2 FY2023Jun 30, 2023$356.31M+57.2%
Q1 FY2023Mar 31, 2023$384.44M+63.5%
Q4 FY2022Dec 31, 2022$306.78M+20.2%
Q3 FY2022Sep 30, 2022$252.55M+9.8%
Q2 FY2022Jun 30, 2022$226.66M-6.9%
Q1 FY2022Mar 31, 2022$235.14M-8.8%
Q4 FY2021Dec 31, 2021$255.25M-5.3%
Q3 FY2021Sep 30, 2021$229.96M+66.3%
Q2 FY2021Jun 30, 2021$243.46M+61.8%
Q1 FY2021Mar 31, 2021$257.73M+325.4%
Q4 FY2020Dec 31, 2020$269.44M+2359.5%
Q3 FY2020Sep 30, 2020$138.25M–
Q2 FY2020Jun 30, 2020$150.44M–
Q1 FY2020Mar 31, 2020$60.59M–
Q4 FY2019Dec 31, 2019$10.96M–

More Keros Therapeutics figures

See a number that looks wrong?